This article is more than 5 years old. Information may no longer be current.
ADA, EASD joint statement on hypoglycemia released
Click Here to Manage Email Alerts
Recommendations for identifying and reporting hypoglycemia in clinical studies have recently been published in a joint position statement from the American Diabetes Association and European Association for the Study of Diabetes, according to a press release.
Current research on hypoglycemia was examined by the International Hypoglycemia Study group to create proposed hypoglycemia levels. The study group also formed recommendations for which levels of hypoglycemia should be reported.
The group made the following recommendations regarding severe hypoglycemia:
Level 1: Levels of 3.9 mmol/L or less constitute a “glucose alert.” Alerts do not need to be reported routinely in clinical studies;
Level 2: Levels of less than 3 mmol/L indicate serious, clinically important hypoglycemia;
Level 3: Severe cognitive impairment may occur with ADA-defined severe hypoglycemia and requires additional assistance for recovery.
“We formed our multi-disciplinary group 3 years ago with a goal to increase awareness of hypoglycemia as a major side effect of current treatment in diabetes by educational activities among the diabetes community — including patients, their families and professionals — to benefit patient care,” Simon R. Heller, MD, professor of clinical diabetes, University of Sheffield, and director of research and development and honorary consultant physician, Sheffield Teaching Hospitals NHS Foundation Trust in the United Kingdom, said in a press release. “We developed the idea that a reclassification of hypoglycemia would be useful and are delighted that both the ADA and [European Association for the Study of Diabetes] have agreed.”
The position statement was simultaneously published in Diabetologia.
Disclosure: Please see the full statement for all authors’ relevant financial disclosures.
Click Here to Manage Email Alerts